RNA Biology

NON-COMMUNICABLE DISEASES / Neurobiology

Research Interests

Genetic diseases caused by defective splicing, RNA splicing mechanisms, RNA metabolism in physiological and pathological neural function

Description of Research

Assessing disease-causing sequence changes and characterization of novel splicing mechanisms: Pre-mRNA splicing is a critical event in the expression of eukaryotic genes allowing the production of different proteins from the same gene. Although the splicing process is a common event in eukaryotic organisms the precise molecular mechanisms that leads to both constitutive and alternative splicing have not been fully characterized, and are vulnerable to a wide range of alterations, which can lead to the development of human disease. In the past few years out research activity has focused on the characterization of unconventional splicing defects involved in human disease, in particular those that result from disruption of as-yet unknown or poorly characterized splicing mechanisms.

Diseases studied include Neufibromatosis (NF-1 gene), long QT syndrome (HERG gene) and Ataxia-telengectasia (ATM gene). We are currently studying the alternative splicing in Voltage-gated sodium channels. These Channels control electrical impulses in nerves, muscles and heart, playing an essential role in the initial phase of action potential. The differences in channel activity, result from mutually exclusive splicing. The characterization and understanding of regulatory elements that control mutually exclusive splicing can eventually lead to novel therapeutic design for the inclusion or exclusion of either exon, providing a therapeutic pathway for related pathologies such as arrhythmias and perception of peripheral pain.

 Regulation of splicing factors. Deregulation of precursor mRNA splicing is associated with many illnesses and has been linked to age‐related chronic diseases. We are interested in the role played by RNA binding proteins in these. Changes that occur with aging are likely to impact the activity of factors that control splicing because of the complexity of the regulatory machinery controlling splicing decisions.

Furthermore, several studies have shown there is an enrichment in pathways such as mRNA binding, RNA processing, and RNA splicing among the age-associated deregulated processes and it is estimated that 50% of all age-associated alterations in alternative splicing are due to changes in splicing factors expression.  In particular, the RNA Biology group is currently focusing in the self-regulation mechanism through which TDP 43 controls its cellular levels. In previous reports, we have shown the importance of several cis-acting elements. Currently, our research is aimed at elucidating the mechanisms behind the age related drop in TDP 43 levels and have started to map epigenetic changes that we believe are responsible for the drop in TDP 43 during ageing.

Past studies in this field have led to the creation of cellular models of TDP 43 aggregation that are currently been used in High through put compound screen for their ability to clear misfolded TDP-43.  Future work is aimed towards understanding the mechanism of action of the top exemplar compounds as well as testing these directly on a Drosophila model constructed in a similar fashion to the cell line that presents and age depend locomotive defect.

Recently, concentrating on disease-related RNA binding proteins, the Group has developed a series of tools that provide an invaluable new way of extensively identifying early potential new medicines for ALS that can clear the serious build-up of TDP-43 aggregates (Cragnaz L, et al Neurobiol Dis. 2021).

Recent Publications

Eloise S. Beer Wells, Laura De Conti, Hyung Chul Kim, Narjes Rohani, Kartik Chundru, Nenad Svrzikapa, Graham McClorey, Laura M. Watts, Ruebena Dawes, Yuyang Chen, Alexandra C. Martin-Geary, Michael J. Griffiths, Sam Scott, Rosemary A. Bamford, Matthew J. Wood, Thomas C. Roberts, Jonathan Mill, Caroline F. Wright, Marco Baralle, Stephan J. Sanders & Nicola Whiffin. Modulating splicing in 5ʹ untranslated regions to treat rare haploinsufficient disease. Genome Med (2026). PubMed link

Wai, H. A., Svobodova, E., Herrera, N. R., Douglas, A. G. L., Holloway, J. W., Baralle, F. E., Baralle, M., & Baralle, D. (2024). Tailored antisense oligonucleotides designed to correct aberrant splicing reveal actionable groups of mutations for rare genetic disorders. Experimental & molecular medicine, 56(8), 1816–1825 PubMed Link

De Marchi, F., Franjkic, T., Schito, P., Russo, T., Nimac, J., Chami, A. A., Mele, A., Vidatic, L., Kriz, J., Julien, J. P., Apic, G., Russell, R. B., Rogelj, B., Cannon, J. R., Baralle, M., Agosta, F., Hecimovic, S., Mazzini, L., Buratti, E., & Munitic, I. (2023). Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder. Biomedicines, 11(6), 1599 PubMed link

Baralle, M., & Romano, M. (2023). Age-Related Alternative Splicing: Driver or Passenger in the Aging Process? Cells, 12(24), 2819 Pubmed link

Pacetti, M., De Conti, L., Marasco, L. E., Romano, M., Rashid, M. M., Nubiè, M., Baralle, F. E., & Baralle, M. (2022). Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications. Disease models & mechanisms, 15(4), dmm049032 PubMed link

Cragnaz, L., Spinelli, G., De Conti, L., Bureau, E. A., Brownlees, J., Feiguin, F., Romano, V., Skoko, N., Klima, R., Kettleborough, C. A., Baralle, F. E., & Baralle, M. (2021). Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance. Neurobiology of disease, 160, 105515 PubMed link

Group Leader

Marco Baralle
ICGEB Trieste, Italy
E-mail: [email protected]
Tel: +39-040-3757201/02
Group Leader CV

Group Members

Maurizio Romano, Visiting Scientist
Laura De Conti, Research Associate
Mohammed Khiat, PhD Student
Giampaolo Cifalà, Graduate Student
Matteo Rosa, Graduate Student